Ophthalmology AdvisorVizz Eyedrops Now Available to Improve Near Vision in Adults

LENZ Therapeutics launched Vizz™ (aceclidine 1.44%), the first FDA-approved topical treatment for presbyopia in adults. The approval follows two phase 3 trials demonstrating near vision improvement within 30 minutes, lasting up to 10 hours. The cholinergic muscarinic agonist induces iris sphincter contraction, creating a pinhole effect that extends depth of focus.

💊 Key Clinical Considerations

• Mechanism of action: Aceclidine causes iris sphincter muscle contraction, producing a pinhole pupil effect that extends focal depth without requiring accommodation, addressing the fundamental optical limitation in presbyopia.
• Efficacy timeline: Phase 3 data demonstrates measurable near vision improvement beginning within 30 minutes of administration, with therapeutic effect maintained for up to 10 hours, providing full-day symptom relief.
• Dosing protocol: Requires sequential administration of two drops per eye (second drop after 2 minutes) from single-dose vial once daily, with 10-minute wait before contact lens reinsertion.
• Drug interactions: When multiple ophthalmic products are prescribed, require 5-minute intervals between administrations to prevent dilution and ensure adequate corneal penetration of each therapeutic agent.
• Storage requirements: Refrigeration required for unopened product; once removed, pouches or vials maintain stability at room temperature for maximum 30 days, requiring patient education on proper handling.

🎯 Clinical Practice Impact

• Patient Communication: Educate patients that Vizz provides temporary optical correction rather than treating underlying lens changes, requiring daily use for sustained benefit and realistic expectations regarding duration of effect.
• Practice Integration: Professional samples available immediately for in-office trials; commercial pharmacy availability expected mid-Q4 2025, allowing early adopter experience before broad prescribing.
• Risk Management: Monitor for cholinergic side effects including headache, brow ache, and potential accommodative spasm; assess contraindications in patients with inflammatory eye conditions or uncontrolled glaucoma.

More in Ophthalmology